Top 10 infectious disease clinical trial failure signals

Infectious disease trials can stop for many reasons that do not mean a drug or vaccine failed scientifically. Some records are shaped by outbreaks, changing standard of care, recruitment windows, funding, public-health logistics, or regulatory pauses. That makes a source-linked ranking more useful than a simple list of stopped trials.

This page focuses on interventions that appear repeatedly in infectious disease stopped-trial records. The table separates likely biological signals, such as efficacy/futility or safety, from the broader stopped-trial count so that one operational stop does not get overread.

Use the ranking as a starting point for review. The most important step is still opening the linked NCT record and reading the sponsor's exact stop language in context.

How to read this ranking

The page groups infectious disease records by listed intervention name and excludes obvious placebo/control-only labels from the ranking.

Likely biological signals include efficacy/futility and safety buckets. Operational, enrollment, funding, regulatory, strategic, and other/unknown stops remain visible in total counts but are not treated as biological failure signals.

In infectious disease, timing and epidemiology matter. A trial can stop because an outbreak changes, enrollment becomes impossible, or the clinical question becomes less relevant. Always verify the primary ClinicalTrials.gov record before drawing a scientific conclusion.